Host: The Japanese Pharmacological Society
Name : The 97th Annual Meeting of the Japanese Pharmacological Society
Number : 97
Location : [in Japanese]
Date : December 14, 2023 - December 16, 2023
Depression has been the most common cause of disability, and affects as many as one in ten individuals at any given time｣ｬboth in worldwide and China. The COVID-19 pandemic in past 3 years increases nearly 30% of the patients with MDD, especially among younger people (COVID-19 Mental Disorders Collaborators, 2021). Depression presents a global health crisis, and there is an urgent need to reduce its burden. Antidepressant treatment, mainly working as to regulate monoamine neurotransmitters, has been the present treatment mainstream in China. While, there still is approximately one-third of treated patients with MDD remaining non-remission. Traditional Chinese medicine (TCM) has a long history of understanding and treating depression, and has been used widely in treating patients with depression in China. More recent clinical trials have been carried out to assess the efficacy and safety of TCM, and to explore the mechanisms of action in relation to the treatment of depression. In this session, we would like to present the effectiveness and application of TCM in the treatment of depression in China, consider their possible mechanisms, and characterize the relationships between their efficacy and mechanisms.
